Jean Chemin,Karine Siquier-Pernet,Michaël Nicouleau,Giulia Barcia,Ali Ahmad,Daniel Medina-Cano,Sylvain Hanein,Nami Altin,Laurence Hubert,Christine Bole-Feysot,Cécile Fourage,Patrick Nitschké,Julien Thevenon,Marlène Rio,Pierre Blanc,Céline Vidal,Nadia Bahi-Buisson,Isabelle Desguerre,Arnold Munnich,Stanislas Lyonnet,Nathalie Boddaert,Emily Fassi,Marwan Shinawi,Holly Zimmerman,Jeanne Amiel,Laurence Faivre,Laurence Colleaux,Philippe Lory,Vincent Cantagrel,Céline vidal

Abstract:Cerebellar atrophy is a key neuroradiological finding usually associated with cerebellar ataxia and cognitive development defect in children. Unlike the adult forms, early onset cerebellar atrophies are classically described as mostly autosomal recessive conditions and the exact contribution of de novo mutations to this phenotype has not been assessed. In contrast, recent studies pinpoint the high prevalence of pathogenic de novo mutations in other developmental disorders such as intellectual disability, autism spectrum disorders and epilepsy. Here, we investigated a cohort of 47 patients with early onset cerebellar atrophy and/or hypoplasia using a custom gene panel as well as whole exome sequencing. De novo mutations were identified in 35% of patients while 27% had mutations inherited in an autosomal recessive manner. Understanding if these de novo events act through a loss or a gain of function effect is critical for treatment considerations. To gain a better insight into the disease mechanisms causing these cerebellar defects, we focused on CACNA1G, a gene not yet associated with the early-onset form. This gene encodes the Cav3.1 subunit of T-type calcium channels highly expressed in Purkinje neurons and deep cerebellar nuclei. We identified four patients with de novo CACNA1G mutations. They all display severe motor and cognitive impairment, cerebellar atrophy as well as variable features such as facial dysmorphisms, digital anomalies, microcephaly and epilepsy. Three subjects share a recurrent c.2881G>A/p.Ala961Thr variant while the fourth patient has the c.4591A>G/p.Met1531Val variant. Both mutations drastically impaired channel inactivation properties with significantly slower kinetics (∼5 times) and negatively shifted potential for half-inactivation (>10 mV). In addition, these two mutations increase neuronal firing in a cerebellar nuclear neuron model and promote a larger window current fully inhibited by TTA-P2, a selective T-type channel blocker. This study highlights the prevalence of de novo mutations in early-onset cerebellar atrophy and demonstrates that A961T and M1531V are gain of function mutations. Moreover, it reveals that aberrant activity of Cav3.1 channels can markedly alter brain development and suggests that this condition could be amenable to treatment.

Cell-specific vulnerability to metabolic failure: the crucial role of parvalbumin expressing neurons in creatine transporter deficiency

Connectomic and behavioral alterations in creatine transporter deficiency are partially normalized by gene therapy

A new rat model of creatine transporter deficiency reveals behavioral disorder and altered brain metabolism

Response to therapy of creatine transporter deficiency caused by a hypomorphic variant in SLC6A8

X-linked creatine transporter deficiency results in prolonged QTc and increased sudden death risk in humans and disease model

X-linked creatine transporter (SLC6A8) deficiency in females: Difficult to recognize, but a potentially treatable disease

Rescue of myocytes and locomotion through AAV2/9-2YF intracisternal gene therapy in a rat model of creatine transporter deficiency

Experimental and Computational Analysis of Newly Identified Pathogenic Mutations in the Creatine Transporter SLC6A8

Novel Corrector for Variants of SLC6A8: A Therapeutic Opportunity for Creatine Transporter Deficiency

Creatine transporter deficiency impairs stress adaptation and brain energetics homeostasis

Energy deficit in parvalbumin neurons leads to circuit dysfunction, impaired sensory gating and social disability

Creatine Transporter Deficiency Presenting as Failure to Thrive: A Case Report of a Novel SLC6A8 Variant Causing a Treatable but Likely Underdiagnosed Genetic Disorder

Epigenetic alterations in creatine transporter deficiency: a new marker for dodecyl creatine ester therapeutic efficacy monitoring

Residual Cystine Transport Activity for Specific Infantile and Juvenile CTNS Mutations in a PTEC-Based Addback Model

Implication of folate deficiency in CYP2U1 loss of function

ATP6V0C variants impair V-ATPase function causing a neurodevelopmental disorder often associated with epilepsy

De novo mutation screening in childhood-onset cerebellar atrophy identifies gain-of-function mutations in the CACNA1G calcium channel gene

Consequences of NaCT/SLC13A5/mINDY deficiency: good versus evil, separated only by the blood-brain barrier

In vivo magnetic resonance spectroscopy in the brain of Cdkl5 null mice reveals a metabolic profile indicative of mitochondrial dysfunctions

Molecular phenotypes segregate missense mutations in SLC13A5 Epilepsy

Sensitive period for rescuing parvalbumin interneurons connectivity and social behavior deficits caused by TSC1 loss